New Urine Test Detects Autism Years Before Traditional Screening Methods

A new study suggests that a simple urine test could identify autism in children years before traditional screening methods allow. This development comes as the prevalence of autism has risen sharply, now affecting one in 31 American children, a stark increase from the one in 150 rate recorded in the early 2000s.

Currently, medical professionals rely on questionnaires, observational tests, and cognitive screenings to diagnose the condition. These conventional approaches often require months or even years to complete. In contrast, scientists at Arizona State University have developed a urine-based test that screens for 17 microbial metabolites, which are molecules produced by microorganisms in the gut.

The research indicates that as many as nine out of 10 children with autism exhibited "extremely high" levels of these metabolites in their urine, a marker that effectively distinguished them from neurotypical children. The test demonstrated approximately 90 percent accuracy and required only a single administration, thereby eliminating the need for extensive, prolonged screening processes.

Experts propose that these metabolites function as altered versions of serotonin and dopamine, the neurotransmitters responsible for regulating mood, cognition, and memory. Disruptions in these chemical pathways may contribute to autistic behaviors, including social difficulties and speech delays. While further research involving larger populations is necessary, the findings offer a pathway to earlier diagnosis and improved quality of life for affected families.

Christina Flynn, a PhD graduate from Arizona State University and the study's lead author, highlighted the significance of the results. "What we've discovered is that 80 to 90 percent of children with autism have extremely high levels of one or more microbially derived metabolites," Flynn stated. She added that utilizing this test would identify young children at high risk for an autism diagnosis and guide treatment strategies for those already diagnosed to help them lead their best lives.

The study, published in the journal Molecular Psychiatry, analyzed data from 52 children with autism and 47 neurotypical children recruited from Arizona, Massachusetts, Tennessee, and Texas. The majority of participants were from Arizona, with most of the autistic group being boys. Participants ranged in age from two to 11 years, with an average age of seven.

Among the 17 metabolites examined, six showed significantly higher levels in the autistic group compared to neurotypical children, with average differences ranging from 29 to 228 percent. Eight specific metabolites derived from tryptophan, an amino acid found in proteins like turkey and tuna, were between 38 and 1,882 percent higher in the autistic group. On average, autistic children possessed three elevated metabolites, whereas typically developing children had none.

James Adams, a professor at Arizona State University and corresponding study author, explained the biological implications. "What's really striking about the bacteria is that they make metabolites that are basically altered versions of serotonin and dopamine," Adams said. He noted that these neurotransmitters affect mood, cognition, and memory, potentially explaining many symptoms in children with autism, such as social communication challenges, anxiety, depression, and attention deficits. Adams further suggested that reducing the levels of these metabolites could help children lead healthier lives and encouraged earlier screening to facilitate timely intervention.

The researchers emphasized that faster diagnosis and earlier intervention are linked to improved behavior, yet current behavioral assessments often involve long wait times. Flynn expressed a hope that this new testing method would lead to a reduction in the stigma and shame often associated with the condition.

Experts suggest that reluctance among parents to pursue diagnostic testing often stems from feelings of inadequacy and a fear of being judged. However, researchers argue that this hesitation is unnecessary, as the condition is fundamentally biological and can be identified through urine analysis. They hope that validating the biological nature of the disorder will encourage families to seek treatment at the earliest possible stage.

The study indicates that these findings illuminate a specific biological mechanism linked to autism. Based on this evidence, the team has proposed a new classification for the disorder, termed 'ASD associated with microbially-derived metabolites,' or ASD-MDM, which they estimate accounts for approximately 90 percent of autism cases.

While early investigations imply that microbiota-based interventions, including fecal transplants, prebiotics, and probiotics, could lower metabolite levels and ameliorate autistic behaviors, the researchers emphasize that further clinical trials are required to confirm these results.

Addressing the emotional toll on families, Dr. Flynn highlighted that the primary struggle for many is the prolonged period of uncertainty. She noted that if this diagnostic test can even slightly reduce that waiting time, it holds significant value, as earlier intervention offers substantial benefits for affected children.